A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

ClinicalTrials.gov ID: NCT06244485

Public ClinicalTrials.gov record NCT06244485. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd antibody-drug conjugates (ADC) in participants with advanced solid tumors.

Study identification

NCT ID: NCT06244485
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Daiichi Sankyo; Industry
Enrollment: 210 participants

Conditions and interventions

Conditions

Advanced Solid Tumor

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 22, 2024 (Actual)
Primary completion: Nov 1, 2028 (Estimated)
Completion: Nov 1, 2028 (Estimated)
Last update posted: Sep 15, 2026

2024 – 2028

United States locations

U.S. sites: 17
U.S. states: 13
U.S. cities: 16

Facility	City	State	ZIP	Site status
City of Hope At Orange County Lennar Foundation Cancer Center	Irvine	California	92618	—
Sharp Memorial Hospital	San Diego	California	92123	—
Brcr Medical Center, Inc Dba Boca Raton Clinical Research	Plantation	Florida	33322	—
University of Hawaii At Manoa	Honolulu	Hawaii	96813	—
University of Chicago Medical Center	Chicago	Illinois	60637	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	—
Memorial Sloan-Kettering Cancer Center (Mskcc) - New York	New York	New York	10065	—
Clinical Research Alliance	Westbury	New York	11590	—
Unc Hospitals	Chapel Hill	North Carolina	27514	—
The Cleveland Clinic Foundation	Cleveland	Ohio	44195	—
Providence Portland Medical Center	Portland	Oregon	97213	—
Mary Crowley Cancer Research Centers	Dallas	Texas	75230	—
Ut Southwestern Medical Center	Dallas	Texas	75390	—
University of Texas M. D. Anderson Cancer Center	Houston	Texas	77030	—
Next Virginia	Fairfax	Virginia	22031	—
Fred Hutchinson Cancer Center	Seattle	Washington	98109	—
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06244485, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 15, 2026 · Synced Oct 16, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06244485 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →